What does ZORYVE cream0.05 — product revenue, net mean?

This metric represents the total net revenue generated from the sale of a specific dermatological product formulation after accounting for returns, discounts, and rebates. It serves as a key indicator of market adoption and commercial traction for the company's therapeutic portfolio within the medical dermatology sector. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of a specific product line as it transitions from clinical development to commercialization.

Arcutis Biotherapeutics, Inc. (ARQT) ZORYVE Cream0.05 — Product revenue, net

Screener

Other product segments

ZORYVE Cream0.3

$27.68M—

ZORYVE Cream0.15

$14.62M—

Similar metrics at other companies

CORTHypercortisolism Products — Product revenue, net

$208.58M+7.3%

XER

XERSProduct revenue, net — Product revenue, net

$91M+34.4%

XER

XERSOther product revenue — Product revenue, net

$0-100%

CORTLifyorli — Product revenue, net

$47.56M—

XER

XERSGvoke — Product revenue, net

$22.55M-3.9%

XER

XERSKeveyis — Product revenue, net

$11.68M+1.7%

Other financials

Income statement

See full

Revenue$129.9M+59.3%

Gross profit$118.9M+60.7%

Operating income$16.4M+212%

Net income$15.0M+194%

EPS (diluted)$0.11+185%

Balance sheet

See full

Cash & equivalents$34.4M-52.9%

Total debt$114.1M+3.6%

Total equity$220.6M+58.7%

Total assets$488.5M+38.6%

Cash flow

See full

Operating cash flow$12.6M—

CapEx$158.0K+103%

Free cash flow$12.5M—

Valuation

See full

Market cap$3.32B+81.4%

Enterprise value$3.4B+82.1%

P/S7.2×+0.2×

Profitability

See full

Gross margin91.1%+2.0pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.5×-0.3×

Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 4:21 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001787306-26-000051

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
ZORYVE cream 0.3%	$35,327	$27,675	$67,997	$51,062
ZORYVE foam	67,377	39,212	117,004	69,452
ZORYVE cream 0.15%	24,231	14,617	45,972	24,836
ZORYVE cream 0.05%	2,926	—	4,286	—
Total product revenue, net	129,861	81,504	235,259	145,350
Other revenue	—	—	—	2,000
Total revenues	$129,861	$81,504	$235,259	$147,350

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.05 — product revenue, net?: Arcutis Biotherapeutics, Inc. (ARQT) reported ZORYVE cream0.05 — product revenue, net of $2.93M in Q2 2026.
What does ZORYVE cream0.05 — product revenue, net mean?: This metric represents the total net revenue generated from the sale of a specific dermatological product formulation after accounting for returns, discounts, and rebates. It serves as a key indicator of market adoption and commercial traction for the company's therapeutic portfolio within the medical dermatology sector. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of a specific product line as it transitions from clinical development to commercialization.